Central Paris is not the location most would pick for an R&D facility, however, nestled down a café-adorned side street close to the border of the city’s 2nd and 10th arrondissements is Moon Surgical, developers of the Maestro surgical system.
Fly Me To The Moon: French Company 'Empowers' Surgeons With Maestro
The Paris-based company has developed Maestro, a lightweight robotic assistant for use in laparoscopic procedures.
More from Robotic Surgery
• By
As it celebrates 75 years shaping the medtech industry, Medtronic invited Medtech Insight to its Minneapolis headquarters to get a closer look at the company’s past, what it’s working on now, and what’s on the horizon.
• By
DUALTO’s double-module option provides enhanced flexibility while cutting down on equipment clutter. Compared to traditional setups, the system reduces OR footprint by 46%, helping staff reclaim space and optimize surgical workflows.
• By
Egg Medical is ramping up efforts to expand international sales of its EggNest scatter radiation protection system to shield X-ray procedure room staff without disrupting workflow. Medtech Insight sat down with Bob Wilson, Egg Medical’s CEO, to discuss the various EggNest systems, marketing opportunities and the competitive landscape.
• By
Enovis has named veteran medtech leader Damien McDonald as its new CEO effective 12 May as the orthopedic company reaffirms first-quarter 2025 revenue guidance of between $555m and $563m. Medtech Insight spoke with Tim Czartoski, Enovis’ president of US surgical and global product and enabling technologies, about the firm’s growth strategy and innovation plans.
More from Surgery
• By
Enovis has named veteran medtech leader Damien McDonald as its new CEO effective 12 May as the orthopedic company reaffirms first-quarter 2025 revenue guidance of between $555m and $563m. Medtech Insight spoke with Tim Czartoski, Enovis’ president of US surgical and global product and enabling technologies, about the firm’s growth strategy and innovation plans.
• By
Vektor Medical is ramping up efforts to bring its vMap technology used to identify arrhythmia sources to more US hospitals, start enrollment in a multinational trial, and commercialize in Europe, pending the CE mark. Medtech Insight sat down with CEO Rob Krummen at LSI 2025 to discuss their plans.